Drug Database
Back to search

Netherlands· NL-4451cb9f54ba

Levetiracetam Teva 250 mg, filmomhulde tabletten

A levetiracetam product containing briljantblauw fcf (e 133) + levetiracetam, registered in Netherlands by Teva B.V.. The same ATC class is registered in 19 of our 19 countries.

ATC N03AX14

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLevetiracetam Teva 250 mg, filmomhuld…ATCN03AX14REGISTER NO.NL-4451cb9f54baPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about briljantblauw fcf (e 133) + levetiracetamAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Levetiracetam is registered in 19 of 19 countries.

Countries holding a registration under ATC N03AX14 (levetiracetam), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 11 of them publish a price we can compare per daily dose
Search levetiracetam products by name

Levetiracetam · ATC N03AX14

19 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of levetiracetam costs, country by country.

Normalised to the WHO defined daily dose (1.5 g), the median price runs from $1.19 in France to $3.10 in Spain — a ×2.6 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Levetiracetam · price per daily dose (1.5 g)

USD · FX 28 Sept 2026

  • ES Spain$3.10
  • CH Switzerland$2.54
  • IT Italy$2.14
  • FR France$1.19
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
BRILJANTBLAUW FCF (E 133) + LEVETIRACETAM
Manufacturer
Teva B.V.
Country
Netherlands (NL)
ATC code
N03AX14
ATC class
Levetiracetam
Defined daily dose
1.5 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/11/701

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

258 interactions on record for levetiracetam.

Graded by severity as the source publishes them — 50 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check levetiracetam against other medicinesHow interaction checks work

Levetiracetam · interactions on record

258 records

  • 50 moderate
  • 3 minor
  • 164 info

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • NabiloneA04AD11moderate

41 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under N03AX14

Levetiracetam, as other registers publish it.

All levetiracetam products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ab1e50eb-7914-456e-a0e3-25599def026a
GET /v1/drugs/ab1e50eb-7914-456e-a0e3-25599def026a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/levetiracetam-teva-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Levetiracetam",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp108775",
  "excipients": [
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
    "INDIGOKARMIJN (E 132)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MAÏSZETMEEL",
    "POVIDON K 30 (E 1201)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "BRILJANTBLAUW FCF (E 133)",
    "LEVETIRACETAM"
  ],
  "leaflet_url": null,
  "authorised_at": "2011/08/26",
  "procedure_number": "EMEA/H/C/002316",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/11/701",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about levetiracetam.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console